Biogen leaps into a showdown between Roche and Regeneron, betting on a potential new franchise player
Plagued by a woeful launch for its Alzheimer’s franchise, Biogen is betting $30 million on some reliable partners at Genentech to come up with a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
